Delcath Q3 2021 Earnings Report
Key Takeaways
Delcath Systems reported product revenue of $522 thousand for the three months ended September 30, 2021, compared to $466 thousand for the prior year period. The company's net loss for the quarter was $7.1 million, compared to a net loss of $5.0 million for the same period in 2020. They closed a $20 million venture debt financing transaction with Avenue Venture Opportunities Fund, L.P. during the quarter.
Product revenue increased to $522 thousand compared to $466 thousand in the prior year period.
Net loss was $7.1 million, compared to $5.0 million for the same period in 2020.
Avenue Venture Opportunities Fund, L.P. provided up to $20 million with an initial $15 million funded at closing.
FDA approved an expanded access protocol for the use of HEPZATO in treating liver dominant metastatic ocular melanoma.
Delcath
Delcath
Delcath Revenue by Segment
Forward Guidance
Delcath is focused on filing the HEPZATO NDA in mid-2022, preparing for the subsequent US launch, and expanding the development of HEPZATO into additional areas.
Revenue & Expenses
Visualization of income flow from segment revenue to net income